Answers are grounded in this paper and cite their sources.
ATG10 is an E2-like ubiquitin-conjugating enzyme that drives Atg12–Atg5 conjugation via unique E3-independent structural adaptations, present in all eukaryotes varying from yeast cells to mammals. Structurally, it adapts a conserved E2 core and an intrinsically disordered region that folds upon binding the E1 enzyme Atg7 to enable crucial trans-thioesterification. This review comprehensively summarizes the multifaceted roles of ATG10 in evolutionary conservation from invertebrates to mammals, highlighting both its canonical autophagic mechanisms and emerging non-canonical functions. As part of the core autophagic machinery, dysregulation or overexpression of ATG10 is heavily implicated in tumorigenesis, epithelial-mesenchymal transition (EMT), and metastasis across multiple malignancies, often serving as a poor prognostic biomarker. Notably, genetic variants in ATG10 are implicated in various human disorders, which further support it as a high-utility therapeutic target.
No takes yet. Share an insight, caveat, or question.
Arpna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: